Landscapes Within - Enclosure and Greeting cards Donating to Alzheimer�s Research

HOME | ABOUT US | OUR DONATIONS | TESTIMONIALS | CONTACT US
    Enclosure Cards Inscribed
    Greeting Cards Inscribed
    Display Packages
    Enclosure Cards Blank
    Greeting Cards Blank
    Boxed Notes

For the last 6 years, we have supported the work of Dr. Norman Relkin at New York's Cornell-Weill Medical Center. Here is information about his latest research:

Alzheimer's Treatment Study Reports Three Years with No Decline in Memory and Function at AAIC 2012

- Also, Special Session Previews the First Three Prevention Trials in Presymptomatic Alzheimer's -

VANCOUVER, July 17, 2012 - The first report of long-term (three-year) stabilization of Alzheimer's disease symptoms with IVIG (Gammagard, Baxter), including no decline on measures of cognition, memory, daily functioning and mood, was reported today at the Alzheimer's Association International Conference 2012 (AAIC 2012) in Vancouver.

In addition, updates were given on three new presymptomatic Alzheimer's disease treatment trials that are beginning soon or in the planning stages. At an AAIC 2012 Featured Research Session titled "Collaboration for Alzheimer's Prevention: Common Issues Across Presymptomatic Treatment Trials," the principal investigators of the three trials described their current status, followed by a panel discussion.

Disappointing results from recent Alzheimer's clinical trials suggest that we may be testing therapies too late in the process of the disease -- that once dementia symptoms are evident, too much damage has been done to the brain for effective treatment.

"Fortunately, improving detection technologies and updated diagnostic guidelines are enabling the detection of early changes in the brain and subtle cognitive deficits that are consistent with what is now known as presymptomatic (or preclinical) Alzheimer's," said William Thies, PhD, Alzheimer's Association chief medical and scientific officer. "People in this stage of the disease are an ideal population for prevention trials to delay the onset or slow the progression of cognitive decline."

http://www.weillcornell.org/relkin/index.html